NasdaqGS - Delayed Quote USD

BioNTech SE (BNTX)

87.21 +0.50 (+0.58%)
At close: April 26 at 4:00 PM EDT
87.01 -0.20 (-0.23%)
After hours: April 26 at 7:42 PM EDT
Currency in EUR All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
3,819,000.00
3,819,000.00
17,310,600.00
18,976,700.00
482,300.00
Cost of Revenue
599,800.00
599,800.00
2,995,000.00
2,911,500.00
59,300.00
Gross Profit
3,219,200.00
3,219,200.00
14,315,600.00
16,065,200.00
423,000.00
Operating Expense
2,315,000.00
2,315,000.00
2,011,800.00
1,138,100.00
505,400.00
Operating Income
904,200.00
904,200.00
12,303,800.00
14,927,100.00
-82,400.00
Net Non Operating Interest Income Expense
349,700.00
349,700.00
29,600.00
-25,800.00
-3,500.00
Other Income Expense
-67,800.00
-67,800.00
620,700.00
145,100.00
-59,900.00
Pretax Income
1,186,100.00
1,186,100.00
12,954,100.00
15,046,400.00
-145,800.00
Tax Provision
255,800.00
255,800.00
3,519,700.00
4,753,900.00
-161,000.00
Net Income Common Stockholders
930,300.00
930,300.00
9,434,400.00
10,292,500.00
15,200.00
Diluted NI Available to Com Stockholders
930,300.00
930,300.00
9,434,400.00
10,292,500.00
15,200.00
Basic EPS
3.87
--
38.78
42.18
0.06
Diluted EPS
3.83
--
37.77
39.63
0.06
Basic Average Shares
240,600.00
--
243,300.00
244,000.00
253,300.00
Diluted Average Shares
242,700.00
--
249,800.00
259,700.00
253,300.00
Total Operating Income as Reported
690,400.00
690,400.00
12,642,700.00
15,283,800.00
-82,400.00
Rent Expense Supplemental
--
--
--
--
2,390.00
Total Expenses
2,914,800.00
2,914,800.00
5,006,800.00
4,049,600.00
564,700.00
Net Income from Continuing & Discontinued Operation
930,300.00
930,300.00
9,434,400.00
10,292,500.00
15,200.00
Normalized Income
983,455.20
983,455.20
8,982,530.40
10,193,251.60
57,130.00
Interest Income
357,600.00
357,600.00
48,500.00
1,500.00
1,600.00
Interest Expense
--
--
16,200.00
5,400.00
2,000.00
Net Interest Income
349,700.00
349,700.00
29,600.00
-25,800.00
-3,500.00
EBIT
904,200.00
904,200.00
12,303,800.00
14,927,100.00
-143,800.00
EBITDA
1,087,600.00
1,087,600.00
12,427,100.00
15,002,300.00
-105,100.00
Reconciled Cost of Revenue
599,800.00
599,800.00
2,995,000.00
2,911,500.00
59,300.00
Reconciled Depreciation
183,400.00
183,400.00
123,300.00
75,200.00
38,700.00
Net Income from Continuing Operation Net Minority Interest
930,300.00
930,300.00
9,434,400.00
10,292,500.00
15,200.00
Total Unusual Items Excluding Goodwill
-67,800.00
-67,800.00
620,700.00
145,100.00
-59,900.00
Total Unusual Items
-67,800.00
-67,800.00
620,700.00
145,100.00
-59,900.00
Normalized EBITDA
1,155,400.00
1,155,400.00
11,806,400.00
14,857,200.00
-45,200.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-14,644.80
-14,644.80
168,830.40
45,851.60
-17,970.00
12/31/2020 - 10/10/2019

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

MRNA Moderna, Inc.
107.97
+1.69%
 
NVAX Novavax, Inc.
4.0900
+3.54%
 
CVAC CureVac N.V.
2.3300
+0.87%
 
REGN Regeneron Pharmaceuticals, Inc.
883.20
-0.84%
 
NTLA Intellia Therapeutics, Inc.
20.76
+3.70%
 
VRTX Vertex Pharmaceuticals Incorporated
397.48
-0.06%
 
BMRN BioMarin Pharmaceutical Inc.
80.91
-1.53%
 
CRSP CRISPR Therapeutics AG
53.91
+0.34%
 
INCY Incyte Corporation
51.68
+0.98%
 
SRPT Sarepta Therapeutics, Inc.
128.77
+1.08%